Subscribe
While immunotherapies continue to gain traction across multiple tumor types, including malignancies of the central nervous system, these agents are also associated with unique adverse events.
Optune Approval Expanded for Newly Diagnosed GBM Patients
Dellann Elliott Mydland on Testing Brain Tumor Tissue
Vanna Dest Discusses the Side Effects of Brain Radiation
Surviving Brain Cancer During Pregnancy
Yana G. Najjar, MD; Deepa Jagtap, MD
Yana G. Najjar, MD; Anand Patel, MD
November 15, 2025
Yana G. Najjar, MD; Kara Schenk, MD
Yana G. Najjar, MD; Albert Dekker, MD
Richard S. Finn, MD; Anthony B. El-Khoueiry, MD; Pierre Gholam, MD; Lipika Goyal, MD
Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD
Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD
Kathleen N. Moore, MD, MS, FASCO; Susana Banerjee, MBBS, MA, FRCP, PhD; David M. O’Malley, MD; Ritu Salani, MD, MBA
Kathleen N. Moore, MD, MS, FASCO; David M. O’Malley, MD